Market Place
Sourcing Support
Ionis to present at upcoming investor conferences
07 Nov 2024 //
PR NEWSWIRE
Ionis reports Q3 2024 financial results
06 Nov 2024 //
PR NEWSWIRE
Ionis FDA Accepts NDA for Donidalorsen in HAE Prophylaxis
04 Nov 2024 //
PR NEWSWIRE
Ionis to hold third quarter 2024 financial results webcast
23 Oct 2024 //
PR NEWSWIRE
Wainzua Recommended For EU Approval For Hereditary Amyloidosis
21 Oct 2024 //
PR NEWSWIRE
Zilganersen granted FDA Fast Track designation for Alexander disease
01 Oct 2024 //
PR NEWSWIRE
Ionis announces proposed public offering of common stock
09 Sep 2024 //
PR NEWSWIRE
Ionis announces pricing of $500.3 million public offering
09 Sep 2024 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
28 Aug 2024 //
PR NEWSWIRE
Ionis Drops Eye Disease Target For Roche-Partnered Drug
01 Aug 2024 //
FIERCE BIOTECH
Ionis reports second quarter 2024 financial results
01 Aug 2024 //
PR NEWSWIRE
Ionis to hold second quarter 2024 financial results webcast
19 Jul 2024 //
PR NEWSWIRE
Ionis To Webcast HALOS Study Results For ION582 In Angelman Syndrome
08 Jul 2024 //
PR NEWSWIRE
Ionis Announces olezarsen FCS NDA Accepted for Priority Review
25 Jun 2024 //
PR NEWSWIRE
Ionis Expands Licensing Agreement With Otsuka For Donidalorsen In Angioedema
18 Jun 2024 //
PR NEWSWIRE
Ionis To Present At TD Cowen Genetic Medicines & RNA Summit
17 Jun 2024 //
PR NEWSWIRE
GSK acquires oligonucleotide drug startup Elsie
07 Jun 2024 //
BIOPHARMADIVE
Ionis Positive Donidalorsen Data In Hereditary Angioedema
31 May 2024 //
PR NEWSWIRE
Ionis to hold donidalorsen Phase 3 data webcast
28 May 2024 //
PR NEWSWIRE
Wainua™ Neuro-Ttransform Isa Data: To Be Presented At 2024 Symposium
23 May 2024 //
PR NEWSWIRE
Biogen, Ionis to discontinue development of experimental ALS drug
17 May 2024 //
REUTERS
Ionis Announces Positive ION582 Angelman Syndrome Topline Results
16 May 2024 //
PR NEWSWIRE
Ionis, Biogen Announce ALS Drug Topline Phase 1/2 Results
16 May 2024 //
PR NEWSWIRE
Ionis to host 2024 virtual Annual Meeting of Stockholders
15 May 2024 //
PR NEWSWIRE
Ionis reports first quarter 2024 financial results
07 May 2024 //
PR NEWSWIRE
Ionis Publishes 2023 Corporate Responsibility Report
25 Apr 2024 //
PR NEWSWIRE
AstraZeneca drops GOLDILOX and the porcupine in R&D update
24 Apr 2024 //
FIERCE BIOTECH
Ionis to hold first quarter 2024 financial results webcast
23 Apr 2024 //
PR NEWSWIRE
Ionis presents pivotal rare disease data, builds toward first solo launch
08 Apr 2024 //
PRESS RELEASE
Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen
07 Apr 2024 //
PR NEWSWIRE
Ionis to Hold Olezarsen Phase 3 Data Webcast
28 Mar 2024 //
PR NEWSWIRE
Positive olezarsen Ph 3 data to be presented at ACC 2024 meeting
25 Mar 2024 //
PR NEWSWIRE
Ionis raises hand in MASH race, shows liver gains in ph. 2 test
13 Mar 2024 //
FIERCE BIOTECH
Ionis announces new chief global product strategy officer
29 Feb 2024 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
28 Feb 2024 //
PR NEWSWIRE
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 2024 //
PR NEWSWIRE
Olezarsen receives Orphan Drug designation from U.S. FDA
15 Feb 2024 //
PRESS RELEASE
Eplontersen granted U.S. FDA Fast Track designation for patients with ATTR-CM
08 Feb 2024 //
PRESS RELEASE
Ionis to hold fourth quarter and full year 2023 financial results webcast
07 Feb 2024 //
PR NEWSWIRE
Ionis’ HAE drug wins in phase 3 setting up approval run to FDA
22 Jan 2024 //
FIERCE BIOTECH
Ionis poised for continued momentum in 2024 with product launches
08 Jan 2024 //
PR NEWSWIRE
FDA approves AstraZeneca, Ionis treatment for rare nerve disease
22 Dec 2023 //
PRESS RELEASE
Otsuka pays Ionis $65M for European rights to rare disease drug
19 Dec 2023 //
FIERCE BIOTECH
Ionis announces European licensing agreement with Otsuka for donidalorsen
18 Dec 2023 //
PR NEWSWIRE
Ionis announces the appointment of Michael Yang to Board of Directors
14 Dec 2023 //
PR NEWSWIRE
Ionis shares positive update from ongoing trial of ION582 for Angelman syndrome
11 Nov 2023 //
PR NEWSWIRE
Ionis presents positive two-year results from the Phase 2 study of donidalorsen
09 Nov 2023 //
PR NEWSWIRE
Ionis to present at upcoming investor conferences
03 Nov 2023 //
PR NEWSWIRE
Ionis reports third quarter 2023 financial results
02 Nov 2023 //
PR NEWSWIRE
Ionis to hold third quarter 2023 financial results webcast
19 Oct 2023 //
PR NEWSWIRE
Ionis statement about results from an analysis of exploratory cardiac endpoints
07 Oct 2023 //
PRESS RELEASE
Ionis shares significant business and pipeline progress at Innovation Day
04 Oct 2023 //
PRESS RELEASE
Eplontersen Phase 3 results published in JAMA show sustained benefit
28 Sep 2023 //
PRESS RELEASE
Roche pays Ionis $60M to license Alzheimer`s, Huntington`s drugs
28 Sep 2023 //
FIERCE BIOTECH
Ionis` metabolic disorder drug lowers high levels of a type of fat in study
27 Sep 2023 //
REUTERS
Ionis to host investor and analyst day event
12 Sep 2023 //
PR NEWSWIRE
Ionis reports second quarter 2023 financial results
09 Aug 2023 //
PR NEWSWIRE
Ionis enters collaboration to advance next generation program targeting Lp
03 Aug 2023 //
PR NEWSWIRE
Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study
31 Jul 2023 //
PR NEWSWIRE
Ionis expands eplontersen agreement with AstraZeneca
28 Jul 2023 //
PR NEWSWIRE
